Daiichi Sankyo (TYO: 4568), a leading pharmaceutical company in Japan, reported a significant year-on-year (YOY) growth of 24.3%, with revenues reaching JPY 436.18 billion (USD 3.0 billion). This Q1’24 result is notable for being the first to not include revenues from Daiichi Sankyo Espha, the company’s generics unit that was divested to Qol Holdings in the previous year.
The company’s global flagship products, the antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and the anti-coagulant Lixiana (edoxaban), continue to drive growth. Enhertu received its sixth indication approval in the United States during Q1’24, expanding its use as a second-line treatment for all HER2-positive tumors, irrespective of tumor location. Co-developed with AstraZeneca, Enhertu has seen a remarkable 59% YOY increase in sales, reaching JPY 129.6 billion (USD 892 million) in global sales. The drug is projected to achieve full-year sales of JPY 508 billion (USD 3.5 billion), solidifying its position as a key growth driver for Daiichi Sankyo.- Flcube.com
